title_logo menu_logo
Pilot & Feasibility Data Search
WARNING! The DiaComp Website will be temporarily unavailable the afternoon of Saturday, May 3.
Upgrades are being made to better suit our users. Thank you for your patience!


There is strong evidence that diabetic complications are linked via dysregulation of common pathways. The NIDDK-sponsored Diabetic Complications Consortium (DiaComp) promotes communication and collaboration between research communities investigating similar pathologic mechanisms in different organs by organizing an annual scientific meeting and funding new research activities.

DiaComp Pilot and Feasibility Program

This program solicits and funds small Pilot and Feasibility (P&F) projects in high impact areas of complications research. Specifically, this program aims to support discovery (hypothesis generating) and innovative (high risk/ high reward) research that is increasingly difficult to support through standard NIH mechanisms. Basic, translational and clinical research proposals are encouraged. Research involving human subjects is limited to observational studies with non-invasive or minimally invasive testing and must have IRB approval that includes the collection and use of human samples for research purposes. Interventional clinical trials are beyond the scope of this program. Awards are expected to prepare the applicant(s) to submit a future investigator initiated project (e.g. NIH R01). Lower priority will be given to applicants who have received DiaComp support in the past three years.
Applications of 5 pages requesting up to $100,000 for one year are due Friday, May 13, 2016.

Current areas of interest include, but are not limited to:

  • Interrogation of human samples or resources with genetics, epigenetics, and/or systems biology. Use of human tissue to identify different molecular and anatomic “subtypes” of end-organ disease, including potential differences between T1D and T2D. Linking and coordination of human samples to existing tissue repositories and databases.
  • Application of stem cells, including induced pluripotent stem (iPS) cells, and regenerative therapies to the repair and reversal of diabetic complications. The development of stem cell based models of disease, including 3D tissue organoids.
  • Use of relevant model systems to accelerate gene X environment (GEI) studies. Pilot studies to assess the role of the microbiome or virome in diabetic complications. Investigation of mechanisms for the possible role of metals in the development of complications and chelation therapy in the prevention or reversal of complications.
  • Pilot studies to non-invasively image fibrosis, inflammation, or function of organs affected by diabetes.
  • Pilot studies to support the development and use of novel cell-based, organoid, or in vivo assays for the discovery and preclinical testing of potential therapies for diabetic complications.

Budget requests should be commensurate with project needs over a one year project period. While average DiaComp P&F awards are $60,000 Total Costs for one year, well justified requests for support of up to $100,000 Total Costs per year will be considered.

International institutions and organizations are eligible for support.

Applications are due May 13, 2016 for September start dates.

For instructions on how to submit a Pilot & Feasibility Funding Program Application to the DiaComp web portal please click the following link: Funding Program Application Submission Basic Training (PDF)

Back to Top

Applicants may request up to $60,000 (direct + indirect costs) Total Costs for one year or well justified requests for support of up to $100,000. A narrative justification should be provided only for any major equipment (cost greater than $5,000) deemed to be necessary for the proposed project. The number of awards will depend upon the number, quality, duration, and cost of the applications received.

Awards will be made as subcontracts from the DiaComp Coordinating and Bioinformatics Unit (CBU) at the Georgia Regents University and not directly by the NIH.

Back to Top

Each application will receive a primary review by multiple external referees and be given scores for Significance, Investigator, Innovation, Approach, Environment and an Overall Score. Scores will range from 1 to 9, where a score of 1 indicates an exceptionally strong application with essentially no weaknesses. A score of 9 indicates an application with serious and substantive weaknesses with very few strengths; 5 is considered an average score. Please note that the Overall Score is NOT an average of the other scores. The DiaComp External Evaluation Committee (EEC) will provide a secondary review of all applications. Written comments will be provided for all reviewed applications. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed. No additional materials may be submitted after the receipt date. Scientists from the applicant institution are in conflict and excluded from review. Final funding decisions will be made by the NIH. All decisions are final and appeals will not be accepted for applications submitted in response to this solicitation.

Back to Top

December 2015 RFA for DiaComp Pilot Projects is posted on DiaComp website, MMPC and other related websites, and notification of the postings is sent to all US academic and research institutions.
May 13, 2016 Grants Submitted to CBU (Dr. Richard McIndoe, CA 4127, Georgia Regents University, Augusta, Georgia, 30912)
September 2016 Projected start date for DiaComp Pilot Project Funding

Back to Top

The application is the standard PHS 398 form including face, abstract, detailed budget, biographical and other support pages (up to 4 pages), and research plan. The research plan (Sections A-D are limited to 5 pages) should include the following sections:

  1. Specific Aims,
  2. Background and Significance,
  3. Preliminary Studies,
  4. Research Design and Methods,
  5. Literature Cited,
  6. Vertebrate Animals
  7. Sharing Plan

submit an electronic version of the application via the DiaComp website (PDF format only please).

Eligible Project Directors/Principal Investigators: Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. New investigators are encouraged to apply, but they must have a full-time faculty position or an equivalent position at non-academic institutions.

Eligible Organizations: Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Non-domestic (non-U.S.) Entity; Small Business; For-Profit Organization (Other than Small Business); State Government; Regional Organization; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Eligible agencies of the Federal government; Faith-based or community based organizations.

Back to Top

Please note that projects devoted to the development of new techniques and tests for the metabolic characterization of mice are NOT responsive to this announcement and are better suited for the MMPC Pilot and Feasibility Grant Program (please see www.mmpc.org for more details). In brief, this program supports applications to:

  • Develop new technologies or miniaturization of existing technologies for use in mice,
  • Develop applications of existing technologies for use in mice,
  • Provide new tests to meet identifiable, outstanding needs necessary to phenotype mouse models of metabolic disease, and
  • Establish new types of mathematical models, informatics, databases or products that augment the mission of the center.

A summary of progress of funded projects is due two months following the completion of the funding period.

DiaComp awardees must follow NIH and HHS policies regarding the sharing of data and resources with the scientific community (http://grants.nih.gov/grants/sharing.htm) and agree to submit to the DiaComp web portal all data and resources resulting from the execution of the awarded application. Data and resources may include, but are not limited to:

  • histology images,
  • protocols,
  • experimental data,
  • microarray data, and
  • progress report(s).

All data and resources generated with DiaComp support will be made immediately available to "active" DiaComp awardees (see below) and publicly available on the DiaComp website: (1) at the time of first publication, or (2) two years from the date of data upload to the DiaComp website (www.diacomp.org). Under certain circumstances, investigators may request an exception to the DiaComp two year public release policy by contacting NIH Program staff and requesting a waiver. Such requests will be reviewed on a case-by-case basis and waivers will be granted only with sufficient and compelling prior justification.

DiaComp awardees are considered "active" and granted full access to the DiaComp website as members of the DiaComp "Steering Committee" for the duration of their funding period plus 4 years. Outgoing awardees may request an extension from NIH Program staff beyond this "active" period.

Proprietary data and resources will be excluded from sharing consistent with NIH and HHS policies (http://grants.nih.gov/grants/sharing.htm).

Financial acknowledgment of award: Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium (DiaComp) using the following text: 'Financial support for this work provided by the NIDDK Diabetic Complications Consortium (DiaComp, www.diacomp.org), grant DK076169'.

For presentations and slides, please use the PowerPoint slide with the funding source logo found in the zip file here - http://www.diacomp.org/images/diacomp-logos.zip - to indicate that DiaComp is a funding sources for your presentation.

Back to Top

Richard McIndoe, Ph.D. (Coordinator)
Coordinating and Bioinformatics Unit
Georgia Regents University
Center for Biotechnology and Genomic Medicine
1120 15th Street, CA4124
Augusta, GA 30912-4810
Phone: 706-721-3542
Fax: 706-721-3688

Back to Top